ASH leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.
Agenda for Hematology Research
The ASH Agenda for Hematology Research serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. Learn more.
Immunologic Treatments of Hematologic Malignancies
Genome Editing and Gene Therapy
Stem Cell Biology and Regenerative Medicine
Venous Thromboembolic Disease
Precision Medicine Initiative
Precision medicine encompasses all approaches that use patient- and disease-specific information to prevent, diagnose, and treat a disease. The increasingly widespread use of genome sequencing and genomic profiling has significantly improved the diagnoses and treatment of hematologic diseases by identifying unique variants that can be targeted with gene-based targeted therapeutic approaches including immunotherapies.
Applying the principles of precision medicine to hematologic diseases is a priority for ASH, and specific research recommendation are described in more detail in the ASH Agenda for Hematology Research.
Learn more about ASH's Precision Medicine Initiative activities:
Recommendations, priorities, and action items for various hematology-related initiatives and areas of research.
The American Society of Hematology (ASH) is the world's largest professional society serving more than 17,000 clinicians and scientists from nearly 100 countries as they work to conquer blood diseases, including cancers such as leukemia, lymphoma, and multiple myeloma. Hematologists have been pioneers in the fields of cancer immunotherapy, cellular therapy, stem cell transplantation, gene therapy, and stem cell biology with many discoveries made by hematologists translated into other fields of medicine. Read more.
The Roadmap for Discovery and Translation in Lymphoma identifies key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. The roadmap was developed by a committee of lymphoma experts after a review of the state of the science in lymphoma conducted at a special ASH Meeting on Lymphoma Biology held in August 2014.
Nearly half of all blood cancer cases are lymphomas, or cancers of the lymphatic system, of which there are numerous unique disease subtypes. While the disease can take many forms, recent advances have better characterized how lymphoma cells proliferate and interact with other cells and tissues, leading to the development of powerful, targeted therapies with fewer side effects than traditional approaches. Read more.
Sickle cell disease (SCD) is the most common inherited red blood cell disorder in the United States, affecting 70,000-100,000 Americans1, 2. Although the molecular basis of SCD was established several decades ago, it has been challenging to translate this knowledge into the development of novel targeted therapies. As recently as the 1960s, this disease was described as a disorder of childhood, because patients rarely survived their teenage years. Today most SCD patients can expect to live into adulthood, but the cost of care and the burden of pain, end-organ injury, and premature death remain high. Read more.
ASH periodically hosts agenda-setting workshops on research in various areas of hematology. These small workshops concentrate on identifying questions that need to be answered in a particular field, determining where gaps exist in the research, pinpointing the windows of opportunity in investigation, and establishing a list of priorities that may form the basis for future National Institutes of Health (NIH) grant opportunities. Read more.
Programs and Awards for Research
ASH supports basic, clinical, and translational hematology investigators at all levels of their careers through its many research award and grant programs.
ASH Bridge Grant
As a demonstration of its commitment to protecting the field and those who have dedicated their careers to the specialty, ASH has established the Bridge Grant to help preserve the careers of its talented member scientists whose vital research will not be accomplished due to across-the-board cuts to the National Institutes of Health (NIH) budget.
ASH Physician-Scientist Career Development Award
The Physician-Scientist Career Development Award immerses medical students between their first and second or second and third years of school in a one-year, full-time research experience in hematology.
ASH Clinical Research Training Institute
The ASH Clinical Research Training Institute (CRTI) is a unique, year-long education and mentoring program for hematology fellows and junior faculty at academic medical centers. CRTI offers a broad education on clinical research methods, research collaborations, statistical analysis, and managing the demands of family and career. The goal of the program is to produce leaders armed with ideas for clinical hematology research and the tools and resources to make their ideas a reality.
ASH Research Training Award for Fellows
The ASH Research Training Award for Fellows (RTAF) is designed to encourage junior researchers in hematology, hematology/oncology, and other hematology-related training programs to pursue a career in academic hematology.
ASH Minority Medical Student Award Program
The Minority Medical Student Award Program (MMSAP) is structured around research experiences of various lengths for students from the United States and Canada in their early years of medical school. Each year, up to 10 minority medical students enrolled in DO, MD, or MD/PhD programs are selected to participate.
ASH-EHA Translational Research Training in Hematology
A joint effort of the American Society of Hematology (ASH) and the European Hematology Association (EHA), Translational Research Training in Hematology (TRTH) is a unique, year-long training and mentoring program focused on helping early stage researchers, including senior postdoctoral fellows and junior faculty, gain the tools necessary to build successful careers in blood-related translational research.